Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lagochiline SCHEMBL14029530 | 0.76 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ACES2CES1 | |
| Lagochiline SCHEMBL9854633 | 0.76 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ACES2CES1 | |
| Lagochiline SCHEMBL9854640 | 0.76 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ACES2CES1 | |
| Lagochiline SCHEMBL29396320 | 0.76 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ACES2CES1 | |
| SCHEMBL15127680 | 0.73 | CYP3A4 (0.53) | CYP3A4MEN1KMT2A | |
| SCHEMBL9854637 | 0.59 | CYP3A4 (0.67) | CYP3A4MEN1KMT2ACES2CES1 | |
| SCHEMBL9854641 | 0.59 | CYP3A4 (0.67) | CYP3A4MEN1KMT2ACES2CES1 | |
| SCHEMBL20668977 | 0.58 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL9854657 | 0.57 | CYP3A4 (0.62) | CYP3A4MEN1KMT2ACES2CES1 | |
| SCHEMBL20225086 | 0.54 | CYP3A4 (0.40) | CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722851-B2 | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A | PAIN THERAPEUTICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722851-B2 | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A | PAIN THERAPEUTICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8492349-B2 | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A | PAIN THERAPEUTICS, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120237951-A1 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS | 2012-09-20 | — | — | US | disclosed |
| US-20090191579-A1 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191579-A1 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009059225-A2 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | PAIN THERAPEUTICS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191579-A1 | ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A | OPRL1, OPRM1, OPRK1 | CYP3A4 2625/4885MEN1 4086/4885KMT2A 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.